Background/Aims: Bevacizumab (Avastin), an anti-vascular endothelial growth factor drug, has been successfully used in the recent years to treat ocular pathologies, mostly by intravitreal administration. The aim of the current study was to assess the off-label topical use of high-dose bevacizumab for the treatment of corneal neovascularization. Methods: Seventeen eyes of 17 patients with corneal neovascularization secondary to various pathologies were included. The patients were treated with topical bevacizumab (25 mg/ml) 4 times daily for 2 weeks. The following parameters were evaluated at baseline and on days 3, 7 and 14: visual acuity, slit-lamp examination, intraocular pressure, heart rate and blood pressure. Color photos were obtained at baseline and on day 14. Results: Eleven eyes (65%) demonstrated regression of corneal neovascularization and/or clearing of corneal opacification. Adverse ocular events were mild and transient, and included eyelid swelling/chalazion and superficial punctate keratitis. Conclusion: Treatment with high-dose topical bevacizumab (25 mg/ml) was effective for corneal neovascularization in nearly two thirds of the eyes treated. Adverse ocular side effects were mild and transient.

Waisbourd M, Goldstein M, Loewenstein A: Treatment of diabetic retinopathy with anti-VEGF drugs. Acta Ophthalmol 2011;89:203-207.
Waisbourd M, Loewenstein A: The use of anti-angiogenic drugs for central retinal vein occlusion (in Hebrew). Harefuah 2010;149:243-244, 261.
Waisbourd M, Loewenstein A, Goldstein M, Leibovitch I: Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drugs Aging 2007;24:643-662.
Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP: Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998;39:18-22.
Fallah MR, Khosravi K, Hashemian MN, Beheshtnezhad AH, Rajabi MT, Gohari M: Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium. Curr Eye Res 2010;35:17-22.
Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI: The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008;115:e33-e38.
Saxena S, Kishore P, Pandey S, Khattri M, Kumar D: Topical bevacizumab for corneal neovascularization after penetrating keratoplasty. Eur J Ophthalmol 2009;19:870-872.
Galor A, Yoo SH: Corneal melt while using topical bevacizumab eye drops. Ophthalmic Surg Lasers Imaging 2010;9:1-3.
Uy HS, Chan PS, Ang RE: Topical bevacizumab and ocular surface neovascularization in patients with Stevens-Johnson syndrome. Cornea 2008;27:70-73.
Wu PC, Kuo HK, Tai MH, Shin SJ: Topical bevacizumab eyedrops for limbal-conjunctival neovascularization in impending recurrent pterygium. Cornea 2009;28:103-104.
Habot-Wilner Z, Barequet IS, Ivanir Y, Moisseiev J, Rosner M: The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization. Acta Ophthalmol 2010;88:862-867.
König Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C: Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009;247:1375-1382.
Bock F, König Y, Kruse F, Baier M, Cursiefen C: Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2008;246:281-284.
Dastjerdi MH, Al-Arfaj KM, Nallasamy N, Hamrah P, Jurkunas UV, Pineda R 2nd, et al: Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009;127:381-389.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.